GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)

The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 26: 237‑245, 2011; DOI: 10.3892/or.2011.1271].

In addition to resistance to cabozantinib, they also exhibited resistance to FDA-approved sorafenib and quizartinib with substantial increases in IC50...Moreover, both omipalisib and radicicol exhibited synergistic effects with cabozantinib, highlighting their therapeutic potential. Overall, we identified metabolic dysregulation as a hallmark of cabozantinib resistance and suggested that targeting metabolic vulnerabilities with PI3K/mTOR or HSP90 inhibitors could be an option to mitigate drug resistance.

The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 33: 2606‑2612, 2015; DOI: 10.3892/or.2015.3861].

The EZA + ENG group demonstrated reduced toxicity relative to free-form EZA across both phenotypic and molecular parameters, suggesting improved biocompatibility and potential for safer drug delivery. These findings support the utility of elastin-based nano carriers in mitigating the developmental toxicity of antiandrogenic therapies.

These findings suggest that Ag-NPs may enhance upstream signaling and drug response rather than directly acting on apoptotic proteins, supporting their potential as nanotechnological co-therapeutics in B-cell ALL. Further mechanistic and in vivo studies are warranted.

In conclusion, our study found a possible association between HERV-E env expression and cervical cancer, as HERV-E is actively transcribed during the progression of cervical lesions. Future studies on the potential interaction of HERV-E env with HPV 16 E7 oncoprotein are likely to elucidate common signaling pathways in the progression of cervical cancer and other HPV-related malignancies.

Overall, this study identifies the crucial function of Mtb GAPDH as a redox sensor and highlights the potential of targeting its pleiotropic cellular functions towards drug discovery. In addition, the efficacy of TCH346 provides an opportunity of drug-repurposing as a strategy for therapy.

This study suggests the altered expression of ribosome biogenesis-related genes in pediatric pre-B acute lymphoblastic leukemia and neuroblastoma. The reported dysregulation suggests a disease-associated disruption in nucleolar function and translational regulation and may contribute to oncogenesis through altered ribosomal assembly, protein synthesis, or proliferative signaling.

Thus, ASE may mitigate liver injury by re-balancing apoptosis-survival signaling and promoting structural recovery. Our interpretation emphasizes that dose, route, and formulation are critical for translational potential.

Given the nature of the concerns, the editors have lost confidence in the results and conclusions. The authors disagree with the retraction.

The PMSMns-IL-12/15-mRNA group exhibited the highest levels of IFN-γ, the greatest infiltration of CD8+ T cells, and the most robust recruitment of NK cells, achieving a potent synergistic antitumor effect. Overall, PMSMns provide a dual benefit: boosting mRNA translation and activating the STING pathway, making them ideally suited for cytokine mRNA-based tumor therapy.

The retraction has been agreed to because the evidence of image re-use and manipulation with multiple previously published articles fundamentally compromises the editors' confidence in the results presented. The authors did not respond to our notice regarding the retraction.